Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded at TD Cowen

TD Cowen upgraded shares of Day One Biopharmaceuticals (NASDAQ:DAWN) to a strong-buy rating in a research report report published on Monday,Zacks.com reports.

DAWN has been the topic of a number of other reports. Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their target price for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Piper Sandler restated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Finally, JPMorgan Chase & Co. cut their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $15.76 on Monday. The business has a fifty day moving average price of $14.29 and a 200 day moving average price of $14.40. Day One Biopharmaceuticals has a fifty-two week low of $10.90 and a fifty-two week high of $18.07. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -15.30 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter last year, the business posted ($0.54) earnings per share. On average, equities analysts expect that Day One Biopharmaceuticals will post -0.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 3,202 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the transaction, the general counsel now owns 26,928 shares of the company’s stock, valued at $376,992. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Samuel C. Blackman sold 2,232 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the completion of the sale, the insider now directly owns 1,127,535 shares of the company’s stock, valued at approximately $15,785,490. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $44,828.00. Following the completion of the transaction, the general counsel now directly owns 26,928 shares in the company, valued at approximately $376,992. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 49,248 shares of company stock valued at $697,082. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. First Turn Management LLC bought a new position in shares of Day One Biopharmaceuticals during the third quarter worth about $13,204,000. Quest Partners LLC grew its stake in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after acquiring an additional 7,668 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Day One Biopharmaceuticals in the third quarter valued at approximately $825,000. TimesSquare Capital Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 8.2% in the third quarter. TimesSquare Capital Management LLC now owns 1,827,695 shares of the company’s stock valued at $25,460,000 after purchasing an additional 139,160 shares during the last quarter. Finally, SteelPeak Wealth LLC lifted its position in shares of Day One Biopharmaceuticals by 9.8% in the third quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock worth $242,000 after purchasing an additional 1,550 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.